Literature DB >> 17434016

Contraindications to oral contraceptive use among women in the United States, 1999-2001.

Emily Shortridge1, Kate Miller.   

Abstract

OBJECTIVE: The prescription requirement for oral contraceptives (OCs) is designed to prevent women with contraindications from using OCs, but this system has never been evaluated. This analysis investigates OC use among women who have contraindications.
METHODS: We use National Health and Nutrition Examination Survey data to estimate the prevalence of contraindications among OC users and nonusers. We associate OC use with contraindication status, controlling for sociodemographic characteristics and access to health services.
RESULTS: Overall, 16% of fecund women aged 20 to 51 years are contraindicated from OC use. The prevalence of contraindications among current OC users is 6%, as compared to 19% among nonusers. Regression results show that OC use is more strongly associated with age, race, marital status and health insurance coverage than with having a contraindication to OCs.
CONCLUSION: The results suggest that under the prescription requirement, screening for contraindications to OCs may be working, but not perfectly. More research is needed to identify more effective and convenient screening methods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434016     DOI: 10.1016/j.contraception.2006.12.022

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  17 in total

1.  Types of combined oral contraceptives used by US women.

Authors:  Kelli Stidham Hall; James Trussell
Journal:  Contraception       Date:  2012-07-06       Impact factor: 3.375

2.  Combined hormonal contraception use in reproductive-age women with contraindications to estrogen use.

Authors:  Julianne R Lauring; Erik B Lehman; Timothy A Deimling; Richard S Legro; Cynthia H Chuang
Journal:  Am J Obstet Gynecol       Date:  2016-04-05       Impact factor: 8.661

3.  Contraindications to progestin-only oral contraceptive pills among reproductive-aged women.

Authors:  Kari White; Joseph E Potter; Kristine Hopkins; Leticia Fernández; Jon Amastae; Daniel Grossman
Journal:  Contraception       Date:  2012-02-24       Impact factor: 3.375

4.  Contraindications to combined oral contraceptives among over-the-counter compared with prescription users.

Authors:  Daniel Grossman; Kari White; Kristine Hopkins; Jon Amastae; Michele Shedlin; Joseph E Potter
Journal:  Obstet Gynecol       Date:  2011-03       Impact factor: 7.661

5.  Perceptions of the safety of oral contraceptives among a predominantly Latina population in Texas.

Authors:  Daniel Grossman; Leticia Fernández; Kristine Hopkins; Jon Amastae; Joseph E Potter
Journal:  Contraception       Date:  2009-10-29       Impact factor: 3.375

6.  Medical contraindications to estrogen and contraceptive use among women veterans.

Authors:  Colleen P Judge; Xinhua Zhao; Florentina E Sileanu; Maria K Mor; Sonya Borrero
Journal:  Am J Obstet Gynecol       Date:  2017-10-27       Impact factor: 8.661

7.  Health insurance coverage and use of family planning services among current and former foster youth: implications of the health care reform law.

Authors:  Amy Dworsky; Kym Ahrens; Mark Courtney
Journal:  J Health Polit Policy Law       Date:  2012-12-21       Impact factor: 2.265

8.  Accuracy of self-screening for contraindications to combined oral contraceptive use.

Authors:  Daniel Grossman; Leticia Fernandez; Kristine Hopkins; Jon Amastae; Sandra G Garcia; Joseph E Potter
Journal:  Obstet Gynecol       Date:  2008-09       Impact factor: 7.661

9.  Hypertension among oral contraceptive users in El Paso, Texas.

Authors:  Kari White; Joseph E Potter; Kristine Hopkins; Jon Amastae; Daniel Grossman
Journal:  J Health Care Poor Underserved       Date:  2013-11

10.  Medical contraindications in women seeking combined hormonal contraception.

Authors:  Hanna Xu; David L Eisenberg; Tessa Madden; Gina M Secura; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2013-11-16       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.